Also Files New Suit Against Vizgen's MERSCOPE
Products for Patent Infringement
PLEASANTON, Calif., June 1, 2023
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in
single cell and spatial biology, today announced that it filed new
patent litigation against NanoString Technologies, Inc. (Nasdaq:
NSTG) and Vizgen, Inc. in the European Unified Patent
Court.
10x Genomics' new lawsuits allege that the use and distribution
of NanoString's CosMx products for RNA detection infringe European
Patents 2 794 928 B1 ("the EP 928 patent") and 4 108 782 B1 ("the
EP 782 patent"). 10x Genomics also filed suit against Vizgen's
MERSCOPE products for infringement of the EP 782 patent. The
asserted patents relate to in situ detection of analytes.
The Unified Patent Court ("UPC") is a new forum for adjudicating
patent infringement and revocation disputes in Europe on a centralized, rather than a
country-by-country, basis. In the newly filed actions before the
Unified Patent Court, 10x Genomics seeks pan-European injunctive
relief against the infringing activities of NanoString and Vizgen
across the EU member states that are part of the new court system.
The member states of the Unified Patent Court are currently
Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Slovenia, and Sweden. Among these UPC member states, the EP
928 patent is in effect in Germany, Netherlands, and France; the EP 782 patent is in effect in all
UPC member states.
In its new lawsuits against NanoString before the Munich Local
Division of the Unified Patent Court, 10x Genomics is seeking
preliminary injunctions against NanoString's CosMx Spatial
Molecular Imager (SMI) instruments and CosMx reagents for RNA
detection in the jurisdictions of the Unified Patent Court in which
the EP 928 and EP 782 patents are in effect.
Previously, on May 17, the Munich
Regional Court found that the EP 928 patent is infringed and issued
an injunction that requires NanoString to stop selling and
supplying CosMx SMI instruments as well as CosMx reagents for RNA
detection in Germany. The full
opinion of the Munich Regional Court is available here:
10xgen.com/munich-spatial-news. The judgment is subject to appeal.
In February 2023, the German Federal
Patent court issued a preliminary opinion finding the asserted
claims of the EP 928 patent valid.
About 10x Genomics
10x Genomics is a life science technology company building
products to interrogate, understand and master biology to advance
human health. Our integrated solutions include instruments,
consumables and software for analyzing biological systems at a
resolution and scale that matches the complexity of biology. 10x
Genomics products have been adopted by researchers around the world
including in all of the top 100 global research institutions as
ranked by Nature in 2021 based on publications and all of the top
20 global pharmaceutical companies by 2021 research and development
spend and have been cited in over 5,000 research papers on
discoveries ranging from oncology to immunology and neuroscience.
Our patent portfolio comprises more than 1,750 issued patents and
patent applications.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
as contained in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. All statements, other than statements of historical
facts, may be forward-looking statements. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as "may," "might," "will,"
"should," "expect," "plan," "anticipate," "could," "intend,"
"target," "project," "contemplate," "believe," "estimate,"
"predict," "potential," "would," "likely," "seek" or "continue" or
the negatives of these terms or variations of them or similar
terminology, but the absence of these words does not mean that a
statement is not forward-looking. These forward-looking statements
include statements regarding 10x Genomics, Inc.'s expectations
regarding litigation and remedies as well as possible outcomes of
litigation. These statements are based on management's current
expectations, forecasts, beliefs, assumptions and information
currently available to management, and actual outcomes and results
could differ materially from these statements due to a number of
factors. The material risks and uncertainties that could affect 10x
Genomics, Inc.'s financial and operating results and cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release include those
discussed under the captions "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents 10x Genomics, Inc. files
with the Securities and Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot provide any assurance that these expectations will prove to
be correct nor can it guarantee that the future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. These
forward- looking statements do not reflect that our success will
depend on our ability to obtain, maintain and protect our
intellectual property rights, intellectual property litigation
could be expensive, time-consuming, unsuccessful, and could
interfere with our ability to develop, manufacture and
commercialize our products or technologies, litigation outcomes are
unpredictable, or there may be changes in our litigation strategy.
The forward-looking statements in this press release are based on
information available to 10x Genomics, Inc. as of the date hereof,
and 10x Genomics, Inc. disclaims any obligation to update any
forward-looking statements provided to reflect any change in our
expectations or any change in events, conditions or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing 10x Genomics, Inc.'s views as of any date subsequent
to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange
Commission, our website (www.10xgenomics.com), press releases,
public conference calls, public webcasts and our social media
accounts as means of disclosing material non-public information and
for complying with our disclosure obligations under Regulation
FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-files-two-new-lawsuits-requesting-preliminary-injunctions-against-nanostrings-cosmx-products-301839927.html
SOURCE 10x Genomics, Inc.